Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 REZILIENT3 Trial for First-Line EGFR Exon 20 Insertion NSCLC
核心洞察
The Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival at a planned interim analysis, showing a statistically significant and clinically meaningful improvement for zipalertinib plus chemotherapy versus chemotherapy alone.
The global, multicenter, randomized, open-label trial enrolled 285 adults with previously untreated, locally advanced or metastatic non-squamous NSCLC harboring EGFR (搜索) exon 20 insertion mutations.
Observed safety for the zipalertinib-containing arm was manageable, and the Independent Data Monitoring Committee recommended unblinding the study.
Taiho Oncology (搜索), Inc., Taiho Pharmaceutical (搜索) Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone, met its primary endpoint of progression-free survival (PFS) at a planned interim analysis. The trial evaluated the combination in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (搜索) (NSCLC) harboring epidermal growth factor receptor (EGFR (搜索)) exon 20 insertion (ex20ins) mutations.
In this analysis, the study demonstrated a statistically significant and clinically meaningful improvement in PFS in the zipalertinib-containing arm. Observed safety for the zipalertinib-containing arm was manageable. Based on these data, the Independent Data Monitoring Committee recommended unblinding the study. The trial will continue to monitor efficacy and safety.
Full results from REZILIENT3 will be submitted for presentation at an upcoming international medical conference. Based on these results, pending discussions with the U.S. Food and Drug Administration (FDA), Taiho Oncology (搜索), Taiho Pharmaceutical (搜索), and Cullinan Therapeutics plan to pursue U.S. regulatory approval for this combination regimen in the first-line setting.
Executive Perspectives
"The positive topline results from the planned interim analysis of REZILIENT3 further support the potential of zipalertinib to meet the high unmet medical need in patients with NSCLC harboring EGFR (搜索) exon 20 insertion mutations," said Harold Keer, MD, PhD, Chief Medical Officer, Taiho Oncology (搜索). "We look forward to pursuing regulatory approval of zipalertinib in combination with chemotherapy in the first-line treatment setting with the goal of providing a new treatment option for this group of patients."
"Zipalertinib is a compound created through Taiho Pharmaceutical (搜索)'s proprietary drug discovery technology," said Fabio Benedetti, MD, Global Chief Medical Officer, Taiho Pharmaceutical. "Achieving positive results in this Phase 3 trial in the first-line setting represents an important milestone for this program. We will continue to work closely with Taiho Oncology (搜索) and Cullinan Therapeutics to bring zipalertinib in combination with chemotherapy to patients as soon as possible."
"Meeting the primary endpoint early at a planned interim analysis marks an important milestone for the REZILIENT3 study and supports the potential role of zipalertinib in the first-line treatment setting," said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. "These topline results give us confidence in the potential for zipalertinib to offer a first-line treatment option for patients with NSCLC with EGFR (搜索) exon 20 insertion mutations."
Trial Design
The REZILIENT3 trial is a multicenter, randomized, controlled, open-label global trial that enrolled 285 adults with previously untreated, locally advanced or metastatic non-squamous NSCLC with EGFR (搜索) exon 20 insertion mutations. The primary objective of the trial is to assess progression-free survival in the zipalertinib plus chemotherapy arm versus the chemotherapy arm.
Mechanism of Action
Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR (搜索). The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations. Zipalertinib is designed as a next-generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer (搜索). Zipalertinib is investigational and has not been approved by any health authority.
Zipalertinib is being developed by Taiho Oncology (搜索), Inc., its parent company, Taiho Pharmaceutical (搜索) Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.
Disease Background
NSCLC is a common form of lung cancer, and up to 4% of all cases globally have EGFR (搜索) ex20ins. In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations, with insertions at exon 20 accounting for up to 12% of these mutations.
Market Response
Following the announcement, Cullinan Therapeutics shares rose 6.33% to $20.84 in after-hours trading, marking a new 52-week high. Wedbush analysts recently reiterated an outperform rating with a $37 price target for Cullinan Therapeutics.